Zacks: Brokerages Expect Kura Oncology (KURA) Will Announce Earnings of -$0.33 Per Share

Analysts expect Kura Oncology (NASDAQ:KURA) to post ($0.33) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). Kura Oncology reported earnings of ($0.39) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The company is expected to announce its next quarterly earnings results on Monday, May 21st.

On average, analysts expect that Kura Oncology will report full-year earnings of ($1.43) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.37). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.93) per share, with EPS estimates ranging from ($3.17) to ($1.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Kura Oncology.

How to Become a New Pot Stock Millionaire

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01).

KURA has been the topic of a number of recent analyst reports. Cann reaffirmed a “buy” rating and set a $30.00 price target on shares of Kura Oncology in a research note on Friday, February 16th. BidaskClub raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 24th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Friday, February 16th. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, Wedbush initiated coverage on shares of Kura Oncology in a research note on Tuesday, December 26th. They set a “buy” rating and a $19.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Kura Oncology has a consensus rating of “Buy” and an average target price of $22.00.

Shares of NASDAQ:KURA traded down $0.95 on Friday, reaching $16.70. 258,821 shares of the company were exchanged, compared to its average volume of 345,009. The company has a quick ratio of 9.44, a current ratio of 9.44 and a debt-to-equity ratio of 0.07. Kura Oncology has a 1-year low of $5.90 and a 1-year high of $24.02. The stock has a market cap of $557.01, a PE ratio of -10.99 and a beta of 4.21.

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in shares of Kura Oncology during the 3rd quarter worth $802,000. American International Group Inc. grew its stake in Kura Oncology by 42.0% in the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after acquiring an additional 4,012 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Kura Oncology in the 4th quarter valued at about $536,000. Alps Advisors Inc. acquired a new stake in Kura Oncology in the 4th quarter valued at about $512,000. Finally, California State Teachers Retirement System grew its stake in Kura Oncology by 24.5% in the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after acquiring an additional 6,200 shares during the last quarter. 58.56% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3341384/zacks-brokerages-expect-kura-oncology-kura-will-announce-earnings-of-0-33-per-share.html.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Inphi  Posts Quarterly  Earnings Results, Hits Estimates
Inphi Posts Quarterly Earnings Results, Hits Estimates
Vicor  Releases  Earnings Results
Vicor Releases Earnings Results
AdEx  Price Tops $1.12 on Major Exchanges
AdEx Price Tops $1.12 on Major Exchanges
Decentraland Trading Up 46% Over Last 7 Days
Decentraland Trading Up 46% Over Last 7 Days
Analyzing Convergys  & Its Peers
Analyzing Convergys & Its Peers
UGI  vs. Sempra Energy  Head-To-Head Analysis
UGI vs. Sempra Energy Head-To-Head Analysis


© 2006-2018 Ticker Report. Google+.